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ABSTRACT
Introduction: Co-occurring psychiatric conditions and
concerning behaviours are prevalent in individuals with
autism spectrum disorders (ASD), and are likely to be
detrimental to functioning and long-term outcomes.
The cognitive rigidity and deficits in emotional literacy
and verbal behaviour that commonly occur in ASD can
adversely affect clinicians’ confidence to identify
concerning behaviours and mental health problems.
There is a need to develop a measure that is tailored
towards individuals with ASD, and differentiates
between symptoms of psychopathology and core ASD
symptoms. Furthermore, it should be modified to
capture internalising symptoms that individuals with
ASD may find difficult or be unable to verbalise. This
protocol describes the intended development and
validation of the Assessment of Concerning Behaviour
(ACB) scale. The ACB will aim to be a multidimensional
measure of concerning behaviours in ASD
incorporating self-report, parent/carer, teacher/
employer and clinician report versions that can be used
across the lifespan and spectrum of intellectual ability.
Methods and analysis: This study will be guided by
the methods described in the US Food and Drug
Administration Guidance for Industry Patient-reported
Outcome Measures. A literature review, cognitive
interviews and focus groups with individuals who have
experience of working or living with ASDs will be used
for item generation. A sample of children and adults
with ASD will complete the ACB, in addition to other
gold standard measures of concerning behaviour in
order to establish the initial psychometric properties of
the scale.
Ethics and dissemination: This study has received
ethical approval from the NHS Research Ethics
Committee: London-Camden and King’s Cross
(ref: 15/LO/0085). Study findings will be disseminated
to healthcare professionals and scientists in the field
through publication in peer-reviewed journals and
conference presentations.
INTRODUCTION
Autism spectrum disorders (ASD) are charac-
terised by restrictive and repetitive interests
and behaviours, impaired social and commu-
nication skills,1 and have a prevalence rate of
approximately 1%.2 ASD is associated with
poor long-term psychosocial impairment3
and substantial burden on the individual,
their family and caregivers in addition to
social and economic burden.4 5
Observational studies have revealed high
levels of concerning behaviours in ASD that
are likely to be of further detriment to long-
term functioning and outcomes. Throughout
this protocol, the term ‘concerning behaviour’
Strengths and limitations of this study
▪ A strength of this study is that it will follow US
Food and Drug Administration guidelines for the
development of patient-reported outcome mea-
sures. Consequently, it will seek extensive input
from service users, parents, families and those
with experience of working with autism spec-
trum disorders.
▪ All participants will be asked to complete the
study questionnaires twice allowing for an
assessment of questionnaire sensitivity to
change in this initial psychometric evaluation of
the instrument.
▪ A potential limitation of this study is that study
questionnaires will be completed in participants’
homes. One may be uncertain about the extent
to which measures are completed independently.
However, some participants will be completing
questionnaires in clinic settings which will allow
us to explore levels of support which informants
require to complete the questionnaire.
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will be used to refer to any behaviours or emotions that
may cause concern for individuals with ASD, their
parents/carers or healthcare professionals. Concerning
behaviours are likely to have a negative impact on the func-
tioning or well-being of the individual with ASD, their
family/carers or wider society. Concerning behaviours
could themselves form important treatment targets or
could be indicative of the presence of a co-occurring con-
dition requiring further investigation. Among others, con-
cerning behaviours that commonly occur in ASD include
aggression, anxiety, phobias, hyperactivity, compulsive
behaviour, depression, suicidal ideation or attempted
suicide and sleep disorders.6–11 While prevalence rates of
co-occurring conditions and concerning behaviours in
ASD vary among studies, this is likely due to methodo-
logical differences in populations assessed (eg, population
or clinic-based samples) and measurement instruments
used (eg, screening or diagnostic tools). Nonetheless,
each of these listed concerns are consistently reported as
occurring more frequently in individuals with ASD com-
pared to typically developing populations.6
However, many clinicians lack conﬁdence in identify-
ing and evaluating co-occurring conditions in ASD. The
presence and heterogeneity of ASD symptoms, intellec-
tual disability and difﬁculty with communication, can
complicate the identiﬁcation of co-occurring conditions
in individuals with ASD who may present with atypical
symptoms of psychopathology.12 Furthermore, diagnostic
overshadowing can lead to symptoms of psychopathology
being wrongly attributed as core ASD symptoms6 (eg,
existing social anxiety may be misinterpreted as lack of
social interest).
Early and accurate identiﬁcation of common concern-
ing behaviours and co-occurring conditions in ASD are
paramount, given that symptoms may be more amenable
to intervention compared to the core symptoms of
ASD.13–17 Furthermore, established concerning beha-
viours and coexisting conditions may be more resistant
to treatment;18 later diagnosis of co-occurring conditions
is related to increased risk of hospitalisation.19
Self-report measures in ASD
Another factor complicating the identiﬁcation of
co-occurring conditions in ASD is the use of self-report
measures. In typically developing populations of youth,
multi-informant reports incorporating self-report mea-
sures are seen as the gold-standard for the assessment of
mental well-being. ASD is associated with cognitive rigid-
ity, difﬁculties with emotion recognition and labelling
(alexithymia), and deﬁcits in social cognition; such
characteristics are likely to lead to differences in the
interpretation of self-report measures that have been
validated in typically developing and other clinical
populations.
A recent meta-analysis has shown that levels of inform-
ant agreement in ASD are similar to levels seen in typic-
ally developing populations. Correlations between
parent and patient report were moderate (r=0.44, 0.42
and 0.36 for externalising problems, internalising pro-
blems, and social skills, respectively;20), indicating some
agreement, yet unique information being provided by
parents and self-reports. It is important that self-report
measures are not overlooked when assessing individuals
with ASD. However, measures should be modiﬁed to the
unique needs of individuals with ASD and should be
validated in this population.
To the best of our knowledge, no questionnaire cur-
rently exists that is targeted towards individuals with
ASD, includes self-report versions, and is able to screen
for coexisting conditions in ASD individuals. This is pos-
sibly because existing measures precede the current
understanding that many people with ASD and related
developmental disorders also have symptoms and disor-
ders that could beneﬁt from other evidence-based
treatment.
Aim
This protocol outlines the intended development and
validation of the ‘Assessment of Concerning Behaviour
Scale’ (ACB). The term ‘concerning behaviour‘ was
chosen for the title of the questionnaire based on feed-
back from patient and public involvement panels (PPI
panels; including parents of individuals with ASD and
individuals with ASD) who disliked the use of the other
terms including ‘psychopathology’, ‘abnormal behav-
iour’, ‘maladaptive behaviour’, ‘symptoms’, ‘challenging
behaviour’ and ‘mental health problems’.
The ACB aims to be a multidimensional screening
measure of concerning behaviours in ASD. The measure
is not intended as a diagnostic tool of co-occurring con-
ditions, but aims to identify the presence of symptoms
that may require further, more in-depth assessment. The
measure will assess the severity of concerning behaviours
to allow for assessment of symptom severity and treat-
ment response over time. It is intended primarily for
clinical use, but will also be appropriate for use as an
outcome in clinical trials.
The study aims to develop self-report, parent/carer,
teacher/employer and clinician report versions that can
be used across the lifespan and spectrum of intellectual
ability. The aim is to make the resulting questionnaire
approximately 40 questions in length that should not
take longer than 20 min to complete.
This project is being conducted as part of a larger
National Institute for Health Research (NIHR)-funded
research project entitled ‘Improving Autism Mental
Health’, reference number: RP-PG-1211-20016.
Methods and analysis
This study will be guided by the methods described in
the US Food and Drug Administration (FDA) Guidance
for Industry Patient-reported Outcome Measures.21 It
will involve an iterative process with the following stages:
concept identiﬁcation, concept elicitation, cognitive
interviews for instrument reﬁnement and instrument val-
idation. The FDA guideline was chosen as the most
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appropriate given its emphasis on patient input in order
to ensure content validity of the questionnaire.
Furthermore, following the FDA guidance will allow the
instrument to be used as an outcome measure in clinical
trials.
PHASE 1: QUALITATIVE DEVELOPMENT OF THE ACB
Tool review
Initial PPI feedback, collected prior to the start of this
project, indicated that a brief, single instrument was
needed to capture and assess the multitude of concern-
ing behaviours experienced by individuals with ASD. A
brief literature review has been conducted and revealed
that no screening tool currently exists that has been
developed speciﬁcally for use in the ASD population.
The research team will draw on extensive clinical experi-
ence in the assessment of individuals with ASD, and
refer to tools commonly used in clinical practice (eg,
the Aberrant Behaviour Checklist, the Developmental
Behaviour Checklist) as well as relevant review articles22
to identify factors to be considered in the assessment of
concerning behaviour in ASD.
Concept identification
Initially, a literature review will identify concerning beha-
viours that commonly occur in ASD to be included in
the questionnaire. A draft version of the instrument
incorporating all these constructs will be created. The
draft version will be presented for review to a panel of
experts with at least 5 years of clinical experience in
ASDs in order to conﬁrm the ﬁndings of the literature
search, and identify missing constructs. A second draft
version will be created based on feedback from the
expert panel.
Concept elicitation
The next stage of the study will involve focus groups
with individuals with experience of living or working
with ASD. Separate focus groups will be conducted with
clinicians and mental health professionals specialising in
child and adult ASD and associated conditions, teachers
working with children with ASD, parents/carers of chil-
dren/adults with ASD and children, young people and
adults with ASD themselves.
The focus groups will explore which concerning beha-
viours and feelings affect people with ASD. The groups
will follow a semistructured format using open-ended
questions to allow participants to discuss their experi-
ences and views. Participants will be asked to discuss
behavioural and emotional issues that are additional to
the core symptoms of ASD. Focus groups will discuss
how these issues present, and how they differ and are
distinct from core ASD characteristics. Participants’ views
on the initial items developed for the questionnaire
(from the literature review and feedback from an expert
panel) will also be sought. Participants will be asked
about items that they feel are important to be included,
as well as items which are irrelevant. Focus groups will
be audio recorded, and each group will include approxi-
mately 4–8 participants (with the exception of child and
adult patient focus groups where a maximum of three
patients will be invited in an attempt to avoid over-
whelming participants). All participants will be asked to
complete a demographic questionnaire during this
session.
After completion of the focus groups, a thematic ana-
lysis, following the principles of thematic analysis pro-
posed by Braun and Clarke,23 will be conducted on the
recorded and transcribed data. The concerning beha-
viours and emotions discussed by participants will be
placed into meaningful clusters and groups. Any ‘clus-
ters’ or themes identiﬁed in the analysis that were not
captured by the literature review and expert panel con-
sultation will be created into items, using language used
by participants in the focus groups, where possible.
A third draft of the questionnaire will be created
incorporating participants’ feedback. Items generated by
the group discussions will be added, while items deemed
irrelevant or not important by group members will be
deleted. It is expected that approximately 150–200 items
will be generated through the literature review and
expert feedback, and the focus groups will reduce this
number to between 40 and 70 items.
PPI panels recruited for the NIHR grant will also be
consulted at this stage, to provide their feedback on this
version of the questionnaire.
Cognitive interviews
All participants taking part in focus groups will be sent a
copy of the third version of the questionnaire (via email
or post) and invited to take part in follow-up interviews
over the telephone. The interviews will follow a semi-
structured interview format. Techniques, such as ‘think-
ing aloud’ and verbal probing, will be used to ensure
that items are correctly understood, and to identify pro-
blems with wording and/or difﬁculties with response
options. In order to reduce participant burden, partici-
pants will be encouraged to focus on items which they
identiﬁed as being particularly difﬁcult or easy to under-
stand, or those which they feel could be reworded more
effectively. It is anticipated that each interview will last
between 20 and 30 min. Based on this feedback, a β
version of the questionnaire will be ﬁnalised. This will
complete the development stage of the study.
PHASE 2: PSYCHOMETRIC EVALUATION OF THE ACB
Main sample
To establish the initial psychometric properties of the
questionnaire, 200 participants will be recruited to com-
plete the ACB, in addition to other standardised mea-
sures of concerning behaviour (table 1). The
questionnaire battery will also incorporate a treatment
report form detailing current medication/therapy/inter-
vention status. The treatment report form will be
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Table 1 Gold standard instruments to be administered to participants in the main sample during the validation stage of the study
Administered to
Measure Key psychometric information
Child with
ASD
Young
person
with ASD
Adult with
ASD
Parent/
carer of
child with
ASD
Parent/carer/
partner of
adult with
ASD Teacher Employer
Clinician/
researcher
Social Communication
Questionnaire (SCQ)
Lifetime Version24
The SCQ shows strong discrimination
between ASD and non-ASD cases
(sensitivity 0.88, specificity 0.7232).
Satisfactory internal reliability of the
whole scale has been reported
(α=0.9033).
X X
Child Behaviour
Checklist (CBCL)
Parent Report28
The Achenbach Manual reports
acceptable internal reliability of the
scales with α values ranging from
α=0.72 for the Anxiety Problems
subscale to α=0.97 for the Total
Problems subscale.28
Eight-day test–retest reliability is
acceptable; correlations ranging from
r=0.80 for the Anxiety Problems
subscale to r=0.94 for the Total
Problems subscale.28
X
Child Behaviour
Checklist (CBCL)
Teacher Report28
Acceptable internal reliability (α
values range from α=0.72 for Somatic
Complaints and Thought Problems
subscales to α=0.95 for Attention
Problems, Rule Breaking Behaviour
and Aggressive Behaviour
subscales28).
Sixteen-day test–retest values range
from r=0.6 for the Withdrawn/
Depressed subscale to r=0.96 for the
inattention items.28
X
Youth Self-Report
(YSR)28
Internal reliability values range from
α=0.67 for the Anxiety subscale to
α=0.95 for the Total Problems
scale.28
Test–retest (8 days) correlations
range from r=0.67 for the Withdrawn/
Depressed subscale to r=0.89 for the
Externalising Behaviour Subscale.28
X X
X X
Continued
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Table 1 Continued
Administered to
Measure Key psychometric information
Child with
ASD
Young
person
with ASD
Adult with
ASD
Parent/
carer of
child with
ASD
Parent/carer/
partner of
adult with
ASD Teacher Employer
Clinician/
researcher
Adult Behaviour
Checklist (ABCL)29
Internal reliability coefficients are
moderate to strong (α=0.67 for
Adaptive Functioning—Friends
subscale to α=0.97 for the Total
Problems subscale).29
Test–retest reliability is acceptable
(r=0.73 for the Withdrawn subscale to
r=0.94 for Substance Use
subscale).29
Adult Self-Report
(ASR)29
Internal reliability estimates are
moderate to strong ranging, from
α=0.51 for the Adaptive Functioning—
Education subscale and Thought
Problems subscale to α=0.97 for the
Total Problems subscale.
Test–retest correlation coefficients
range from r=0.71 for the Adaptive
Functioning—Job subscale to r=0.99
for the Substance Use—Drugs
subscale.29
X
Aberrant Behaviour
Checklist (ABC)30
This scale has 5 subscales with α
coefficients ranging between 0.86 for
Inappropriate Speech to 0.94 for
Hyperactivity.30
The 4-week test–retest for all of the
subscales are between r=0.96–
0.98.30
X X X X
The Modified Overt
Aggression Scale34 35
The inter-rater reliability of this
instrument has been assessed in a
sample of adults with ID
(ICC=0.93;36).
X X X X
Clinical Global
Impressions Scale
(CGI)
The CGI correlates well with
well-known efficacy scales.37 38
The CGI is used in many treatment
trials.39
X
Good internal reliability for both
subscales (α=0.89 for Demand
X
Continued
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completed by parent/carers of children with ASD, and
adults with ASD will be asked to report on their own
treatment. Where adults are unable to report on their
own treatment, their parent/carer/relative/partner will
be asked to complete the treatment report form. The
Social Communication Questionnaire24 will be com-
pleted by parents/caregivers at study entry for character-
isation of the study sample.
Participants’ questionnaire battery will be presented in
HealthTracker™, a web-based platform for online com-
pletion (www.healthtracker.co.uk) that is currently being
used in two EU FP7 projects—the Suicidality: Treatment
Occurring in Paediatrics (STOP study; http://www.
stop-study.com) and the Managing the Link and
Strengthening Transition from Child to Adult Mental
Health Care (MILESTONE) project (http://www.
milestone -transitionstudy.eu). HealthTracker™ has also
been used in a previous questionnaire development and
validation study.25 The web-based questionnaires will
follow the principles of data protection, security levels
for health data, have an audit trail and Good Clinical
Practice compliance. Participants will be given a unique
ID number and log-in information, and will be asked to
complete the questionnaires independently. All partici-
pants, including those with literacy issues, will have the
option of going through the questionnaires over the
phone with a member of the research team. Participants
will also be able to complete paper versions of the ques-
tionnaires if requested. Questionnaire completion
should not take longer than approximately 60 min for
adults and 40 min for children.
Participant medical records will be accessed to validate
the ACB against details of diagnoses obtained from
patient case notes as well as against Development and
Well-being Assessment (DAWBA26) diagnoses, IQ and
treatment/medication status if they are available in case
notes. Consent will be obtained to access medical notes.
For children recruited via schools, the research team will
also request details about IQ, educational attainment
and diagnoses from school records. Parental consent
will be obtained to do this. Where measures of IQ are
not available from participant medical/school records, a
brief measure of IQ will be collected by the research
team (see table 1).
All participants will be asked to complete the question-
naire battery twice: at study entry and again between 4
and 6 months after initial completion. This is to allow
for analysis of the stability of the questionnaire. Based
on clinical experience, 4–6 months was chosen as an
appropriate period of time in which one would antici-
pate change in symptoms (eg, in relation to treatment
response). Information on treatment, diagnoses and
other relevant information will be gleaned from medical
records in order to estimate when change of scores
would be expected.
Approximately 50 participants, along with their
parent/carer/relative/partner, teacher/employer and
clinician will be asked to complete the ACB and gold
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standard questionnaires (see table 1) again, 1 week after
their initial completion, to provide a measure of test–
retest reliability. However, interim analyses will be con-
ducted after 25 participants have completed the
measure at 1 week. If a statistically signiﬁcant correlation
is evident, no further participants will be asked to com-
plete measures again after 1 week. Since some of the
items measured in the ACB are likely to be related to
changeable constructs, a priori decisions will be made
about items in the ACB that are expected to remain
stable over 1 week.
Augmented sample for factor analysis
In order to permit a factor analysis of the ACB, we will
then aim to augment the main sample with a further
150 children and 150 adults with ASD in addition to
their parent/carer/relative/partner, teacher/employer
and clinician, who will complete the ACB only. Attempts
will be made to ensure that the augmented sample is
comparable with the main sample on age, gender, IQ
and recruitment source. Participants in the augmented
sample will be asked to complete the ACB, in addition
to providing demographic information. Similar to the
main sample, the ACB will be presented to participants
in HealthTracker™. Participants will only be required to
complete the ACB once, after which, their involvement
in the study will end.
Recruitment
Information sheets (and age-appropriate information
sheets where relevant) will be provided for all partici-
pants. Written informed consent and assent (where
appropriate) will be obtained from all participants
taking part in either stage of the research project. The
purpose of the study and issues surrounding consent
and conﬁdentiality will be outlined to participants
before consent is obtained.
Where the research team has doubts about a person’s
capacity to consent, a capacity checklist will be com-
pleted with the participant. If a participant is unable to
provide informed consent, consent for their participa-
tion will be gained from their legal guardian or a per-
sonal consultee, and assent will also be sought from the
participant.
Phase 1 recruitment
Children (7–12 years), young people (13–18 years) and
adults with ASD, parent/caregivers of individuals with
ASD, and teachers and clinicians who work with indivi-
duals with ASD will be recruited. Owing to the group-
based nature of the focus groups, adults lacking capacity
to consent will not be able to partake in focus groups
and will be excluded. Separate focus groups will be con-
ducted with each group (children with ASD, young
people with ASD, adults with ASD, parents/carers, tea-
chers and clinicians). Approximately 3–8 participants
will take part in each focus group. No more than 60
participants in total will take part in the instrument
development stage of the research.
Participants with ASD, and parents of individuals with
ASD, will be recruited from clinics within participating
trusts that see people with ASD and related developmen-
tal disorders. The research team or clinicians involved in
the patients’ usual care will invite individuals with ASD
and parents of children with ASD to take part. Attempts
will be made to recruit individuals with a range of con-
cerning behaviours and intellectual abilities, through
consultation with the clinician involved in the patient’s
usual care, and through recruitment from clinics specia-
lising in different disorders associated with ASD.
Furthermore, the sample will also consist of individuals
recruited from non-clinical sources in order to include
participants who have received a diagnosis but are not
currently accessing clinical services. This will include
recruitment from schools catering to a range of intellec-
tual abilities and from community sources, such as
support groups.
Clinicians who work with ASD in participating trusts
will be invited to take part in focus groups and follow-up
cognitive interviews. Teachers will be invited by contact-
ing local autism-specialist schools in the London area via
invitation letter to the head teacher.
Inclusion criteria
▸ Children (aged 7+ years), young people and adults
with ASD (via clinician/researcher invite).
▸ Parents/carers of children with ASD.
▸ Teachers working within autism specialist schools for
children and young people in the London area.
▸ Clinicians who work within healthcare settings in par-
ticipating trusts that see children and/or adults with
ASD and associated developmental conditions.
Exclusion criteria
▸ Participants who do not have a reasonable level of
English; a reasonable level of English, will be
required to engage in the focus group/cognitive
interviews.
▸ Individuals with ASD who are not verbal will not be
included in focus groups/interviews. However, carers,
teachers and parents of that person may still take part
in their respective groups if they wish.
▸ Adults lacking capacity to consent will not be
included in focus groups/interviews.
▸ If children, young people, or adults with ASD are not
able to (or expected to not be able to) partake in the
focus groups, they will be excluded from the instru-
ment development stage. Discussions with clinicians
involved in the patient’s usual care/caregivers/the
patient themselves prior to consent will be used to
explore the individual’s ability to partake in focus
groups, and the levels of distress it would potentially
cause them.
Phase 2 recruitment
Main sample. Individuals with ASD (children, young
people and adults) and their parents/caregivers/
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relatives/partners, teachers/employers and clinicians
will be invited to take part (see below for inclusion cri-
teria). Individuals with ASD will be recruited via clin-
ician/researcher invite as well as via poster
advertisements within healthcare and community set-
tings, social media and websites for ASD support groups.
Individuals with ASD will also be recruited from autism-
speciﬁc schools and residential settings. Researchers will
primarily be recruiting participants via clinics within par-
ticipating trusts; the aim is to recruit approximately 75%
via this method. This is to ensure access to medical
notes for as many participants as possible. However, par-
ticipants will not be excluded if they are not currently
under the care of participating trusts. Parental consent
will be obtained to request details about the child’s IQ,
educational attainment and diagnosis from school
records.
Parents of children with ASD will be asked to provide
details of their child’s teacher and clinician, and will
provide consent for the research team to contact them
and invite them to complete the study questionnaires.
Adults with ASD will be asked to provide details of
another person who knows them well (either a parent/
caregiver/relative/partner) who would be able to com-
plete a questionnaire about them. Adults with ASD will
also be asked to provide contact details for their clin-
ician and their employer (if applicable and
appropriate).
Augmented sample. A similar recruitment approach will
be adopted for the augmented sample to ensure com-
parability with the main sample on demographic
characteristics and source of recruitment.
Inclusion criteria
▸ Children (aged 7+ years), young people and adults
with ASD.
▸ Parents/carers, teachers and clinicians of individuals
with ASD.
▸ Partners/caregivers/relatives/partners and employers
of adult individuals with ASD, when parents and tea-
chers are not relevant or appropriate.
▸ Adults lacking capacity to consent will be included in
the instrument validation stage of the study as long as
informed consent for their participation is obtained
from a legal guardian/personal consultee.
Exclusion criteria
▸ If researchers have doubts about a participant’s cap-
acity to consent after completing a capacity checklist,
and an appropriate personal consultee cannot be
identiﬁed, they will not be consented into the study.
Doubts regarding capacity to consent will be dis-
cussed with the CI.
▸ If children, young people, or adults with ASD are not
able to (or expected to not be able to) complete
questionnaires, they will be excluded from the study.
Discussions with clinicians involved in the patients’
usual care/caregivers/the patient themselves prior to
consent will be used to explore the individual’s ability
to complete questionnaires, and the levels of distress
it would potentially cause them.
▸ Participants who do not have a reasonable level of
English will be excluded from the instrument valid-
ation stage of the study. This is because a reasonable
level will be required to complete questionnaires
which will only be available in English at the valid-
ation stage.
Phase 2 sample size
Main sample. For this stage of the study, we will aim to
recruit 200 people with ASD (approximately 100 adults
and 100 children), in addition to their parent/carer/
partner, teacher/employer and clinician, to complete
the ACB and gold standard measures for analysis of reli-
ability and validity of the ACB (see table 1). In a popula-
tion cohort of people with ASD, the approximate IQ
distribution was as follows: 15% had IQ<50, 40% had
50<IQ<70, 40% had an average IQ (70<IQ<115) and 5%
had an above average IQ (IQ>115).18 We will aim to
recruit across the spectrum of IQ in similar proportions
to this population sample to provide a representation of
a ‘typical’ ASD population, and ensure generalisability
of ﬁndings. Attempts will be made to obtain estimates of
IQ for individuals with ASD from school/medical notes.
However, where this is not available, the research team
will collect a brief measure of IQ through completing
the Wechsler Abbreviated Scale of Intelligence27 during
brief home visits to participant homes. All parents, care-
givers, relatives and partners will be asked to provide an
estimate of the cognitive functional age of the individual
with ASD on their demographic questionnaire.
Augmented sample
In order to permit a factor analysis of the items with the
measure, we will augment the main sample with a
further 150 children with ASD and 150 adults with ASD
who will complete the ACB only. Where possible,
parents/carers, teachers/employers and clinicians will
also be recruited into this augmented sample, and asked
to complete the appropriate version of the ACB. This
augmented sample will be combined with the main
sample to ensure that there will be at least six respon-
dents per item for both the child and adult versions of
the ACB for the factor analysis.
Analysis strategy
Instrument development
Data collected during focus groups will be recorded and
transcribed verbatim. Thematic analysis and content
analysis will be used to organise focus group data into
meaningful themes. The NVivo software package will be
used to manage qualitative data generated from partici-
pant focus groups. The data analysis will follow the six
steps to thematic analysis proposed by Braun and
Clarke.23
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Instrument validation
Quantitative data will be analysed using the SPSS and
the MPlus statistics packages.
Reliability
Internal consistency. Cronbach’s α values will be calcu-
lated for the total scale and subscales identiﬁed by
factor analysis. α Values of 0.80, or higher, are commonly
accepted as evidence of adequate internal reliability. An
‘if item deleted’ analysis will be conducted to identify
whether any items should be dropped from the scale.
Test–retest reliability. To assess test–retest reliability, intra-
class correlation coefﬁcients will be calculated on sub-
scale and total scores which are expected to remain
stable. As this is an exploratory study, weighted Cohen’s
κ values will be also calculated to assess test–retest reli-
ability at the item level. Coefﬁcients will be established
separately for children and adults, and also for parent/
carer/relative/partner, teacher/employer and clinician
reports on samples of approximately 50 questionnaires
completed approximately 1 week after initial comple-
tion. For scores that are expected to remain stable, we
anticipate a high intraclass correlation of 0.80, for
which a sample of 37 would provide a 95% CI of width
0.2. Intraclass correlation coefﬁcients will also be
calculated to assess the longer term stability of the measure
4–6 months after initial completion of the questionnaire.
Inter-rater reliability. Intraclass correlations will be used to
assess inter-rater agreement between pairs of scores pro-
vided by two different raters (eg, self-report vs parent/
carer; parent/carer vs teacher). Coefﬁcients will be cal-
culated at the subscale and total score levels. As this is
an exploratory study, weighted Cohen’s κ values will also
be calculated to assess inter-rater reliability at the item
level.
Validity
Scale comparisons will be used to investigate the concur-
rent convergent validity of the ACB. Pearson correlation
coefﬁcients will be calculated to explore the association
between ACB scores and other measures collected that
are commonly used in clinical practice (table 1; subscale
scores will be investigated where appropriate).
Receiver operating characteristic (ROC) analyses will
be conducted to evaluate the discriminative power of
the instrument. Currently, there is no existing gold-
standard instrument for the identiﬁcation of concerning
behaviour in ASD. Therefore, ROC analyses will be con-
ducted using scores from the Achenbach suite of mea-
sures (Child Behaviour Checklist;28 Youth Self-Report;28
Adult Behaviour Checklist;29 Adult Self-Report29), and
the Aberrant Behaviour Checklist30 collected as part of
the validation phase of this study (see table 1). Where
data are available, ROC analyses will also be conducted
according to the presence or absence of clinical and/or
the structured DAWBA diagnosis taken from the
patient’s medical notes. For clinical cut-offs, we are able
to estimate the ROC against the structured psychiatric
assessment with a 95% CIs of ±0.12 (assuming a false-
positive rate of 20% and true-positive rate of 28%31). In
addition, independent samples t tests will be performed
with grouping variable DAWBA and/or clinical diagno-
ses (coded 1 for positive and 0 for negative diagnosis) to
assess differences in ACB scoring and the ability of the
ACB to distinguish between different groups of patients.
Factor analysis. To identify meaningful item clusters,
exploratory factor analysis for ordinal data will be used
for exploratory analyses of the item pool. If required
(eg, in the case of Likert scales having fewer than ﬁve
response options, substantial ﬂoor/ceiling effects, highly
skewed items, data not missing at random), item factor
analysis will be conducted in MPlus (latent trait model)
to avoid biased parameter estimates.
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cipants. The aim of the study is to develop and validate
an instrument to assess mental health and concerning
behaviour in ASD. The study output will provide a clinic-
ally relevant tool, predominantly for use with individuals
with ASD. Future research will require the recruitment of
a second sample of participants in order for
Conﬁrmatory Factor Analysis to be conducted on the pro-
posed factor structure resulting from this study. It is also
hoped the instrument will be effective as an outcome
measure for use in ASD intervention research. If the
instrument is found to be a valid measure of concerning
behaviour in ASD, future research will also need to assess
the sensitivity of the instrument to change following inter-
vention in a randomised controlled trial. The ﬁndings of
this study will be disseminated to healthcare professionals
and scientists in the ﬁeld through publication in peer-
reviewed journals and conference presentations.
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